Incyte’s ruxolitinib franchise, made up of blockbuster JAK inhibitor Jakafi and its topical counterpart Opzelura, have been ...

A recent study published in the Dermatology and Therapy journal confirmed the effectiveness and safety of upadacitinib, a ...

SAN FRANCISCO - Nektar Therapeutics (NASDAQ:NKTR) announced today that its drug candidate, rezpegaldesleukin, has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for ...

Mirikizumab showed superior maintenance efficacy over most treatments for ulcerative colitis (UC), according to a network ...

Data from a retrospective multicenter study, along with a review of previous trials, supported the real-world utility of ...

Apogee Therapeutics develops therapies for inflammatory autoimmune diseases. Find out why I'm bearish on APGE stock.

Patients with atopic dermatitis aged 2 years and older who used tapinarof cream 1% had significant improvements in various patient-reported outcomes.

Panelists discuss the pathophysiology of atopic dermatitis (AD), focusing on the role of type 2 inflammation, and explore how AD can serve as an entry point to the atopic march in children, leading to ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Members of an international team of experts in atopic dermatitis (AD) have recommended oral JAK inhibitors for patients ...

Contact dermatitis develops when your skin comes in contact with a substance that irritates your skin, or one to which you are allergic. The classic symptoms of contact dermatitis are an itchy, red ...

A representative case of adult atopic dermatitis after successful proactive topical corticosteroid ... and 19% for baricitinib, upadacitinib, and abrocitinib (21), respectively. A detailed comparison ...

atopic dermatitis, and recent onset of comorbid autoimmune disease. “In the adult world, clinicians might say, if it’s that bad, go ahead and stabilize the disease with systemic ...